

# Emmanuel Deshayes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6419167/publications.pdf>

Version: 2024-02-01

47  
papers

1,176  
citations

471371

17  
h-index

414303

32  
g-index

53  
all docs

53  
docs citations

53  
times ranked

1796  
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantification of Myocardial Blood Flow in Absolute Terms Using 82Rb PET Imaging. JACC: Cardiovascular Imaging, 2014, 7, 1119-1127.	2.3	144
2	Introduction to Radiobiology of Targeted Radionuclide Therapy. Frontiers in Medicine, 2015, 2, 12.	1.2	131
3	Extended liver venous deprivation before major hepatectomy induces marked and very rapid increase in future liver remnant function. European Radiology, 2017, 27, 3343-3352.	2.3	108
4	Localized Irradiation of Cell Membrane by Auger Electrons Is Cytotoxic Through Oxidative Stress-Mediated Nontargeted Effects. Antioxidants and Redox Signaling, 2016, 25, 467-484.	2.5	68
5	Additional Benefit of F-18 FDG PET/CT in the Staging and Follow-up of Pediatric Rhabdomyosarcoma. Clinical Nuclear Medicine, 2011, 36, 672-677.	0.7	65
6	Radium 223 dichloride for prostate cancer treatment. Drug Design, Development and Therapy, 2017, Volume 11, 2643-2651.	2.0	65
7	Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. , 2019, 7, 29.		63
8	Perioperative impact of liver venous deprivation compared with portal venous embolization in patients undergoing right hepatectomy: preliminary results from the pioneer center. Hepatobiliary Surgery and Nutrition, 2019, 8, 329-337.	0.7	60
9	Liver venous deprivation versus portal vein embolization before major hepatectomy: future liver remnant volumetric and functional changes. Hepatobiliary Surgery and Nutrition, 2020, 9, 564-576.	0.7	43
10	Intraocular sarcoidosis: association of clinical characteristics of uveitis with findings from <sup>18</sup> F-labelled fluorodeoxyglucose positron emission tomography. British Journal of Ophthalmology, 2012, 96, 99-103.	2.1	39
11	Comparison of commercial dosimetric software platforms in patients treated with <sup>177</sup> Lu- <sup>111</sup> DOTATATE for peptide receptor radionuclide therapy. Medical Physics, 2020, 47, 4602-4615.	1.6	34
12	Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [177Lu-DOTA0, Tyr3]-octreotate. EJNMMI Research, 2018, 8, 103.	1.1	31
13	Study protocol of the HYPER-LIV01 trial: a multicenter phase II, prospective and randomized study comparing simultaneous portal and hepatic vein embolization to portal vein embolization for hypertrophy of the future liver remnant before major hepatectomy for colo-rectal liver metastases. BMC Cancer, 2020, 20, 574.	1.1	29
14	Optimization of the future remnant liver: review of the current strategies in Europe. Hepatobiliary Surgery and Nutrition, 2021, 10, 350-363.	0.7	29
15	Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger Radioimmunotherapy. Clinical Cancer Research, 2019, 25, 4775-4790.	3.2	26
16	First in-human radiation dosimetry of 68Ga-NODAGA-RGDyK. EJNMMI Research, 2017, 7, 43.	1.1	24
17	SBRT planning for liver metastases: A focus on immobilization, motion management and planning imaging techniques. Reports of Practical Oncology and Radiotherapy, 2017, 22, 103-110.	0.3	21
18	<sup>18</sup> F-FDG PET/CT Findings in a Patient With Isolated Intracranial Rosai-Dorfman Disease. Clinical Nuclear Medicine, 2013, 38, e50-e52.	0.7	17

#	ARTICLE	IF	CITATIONS
19	Evaluation of response after SBRT for liver tumors. Reports of Practical Oncology and Radiotherapy, 2017, 22, 170-175.	0.3	17
20	The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells. Oncotarget, 2017, 8, 37061-37079.	0.8	16
21	Radiolabeled Antibodies Against M $\beta$ llerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer. Journal of Nuclear Medicine, 2018, 59, 1234-1242.	2.8	15
22	From the target cell theory to a more integrated view of radiobiology in Targeted radionuclide therapy: The Montpellier group's experience. Nuclear Medicine and Biology, 2022, 104-105, 53-64.	0.3	14
23	Imaging angiogenesis in atherosclerosis in large arteries with <sup>68</sup> Ga-NODAGA-RGD PET/CT: relationship with clinical atherosclerotic cardiovascular disease. EJNMMI Research, 2021, 11, 71.	1.1	12
24	Exogenous thyrotropin improves renal function in euthyroid patients, while serum creatinine levels are increased in hypothyroidism. CKJ: Clinical Kidney Journal, 2013, 6, 478-483.	1.4	11
25	Extended Liver Venous Deprivation Leads to a Higher Increase in Liver Function than ALPPS in Early Assessment. Journal of Gastrointestinal Surgery, 2017, 21, 1754-1755.	0.9	11
26	Deportalization, Venous Congestion, Venous Deprivation: Serial Measurements of Volumes and Functions on Morphofunctional <sup>99m</sup> Tc-Mebrofenin SPECT-CT. Diagnostics, 2021, 11, 12.	1.3	9
27	Two-stage hepatectomy for colorectal liver metastases: Pathologic response to preoperative chemotherapy is associated with second-stage completion and longer survival. Surgery, 2019, 165, 703-711.	1.0	7
28	Hepatobiliary Scintigraphy and Glass <sup>90</sup> Y Radioembolization with Personalized Dosimetry: Dynamic Changes in Treated and Nontreated Liver. Diagnostics, 2021, 11, 931.	1.3	7
29	<sup>99m</sup> Tc-mebrofenin hepatobiliary scintigraphy and volume metrics before liver preparation: correlations and discrepancies in non-cirrhotic patients. Annals of Translational Medicine, 2021, 9, 795-795.	0.7	7
30	F-18 FDG PET/CT Imaging in a Case of Primary Choriocarcinoma in the Retroperitoneum. Clinical Nuclear Medicine, 2009, 34, 449-451.	0.7	6
31	AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications. Pharmaceuticals, 2022, 15, 234.	1.7	6
32	Quantification and monitoring of PET/CT data in multicentre trials: The Swiss SAKK 56/07 trial experience. Medecine Nucleaire, 2017, 41, 259-266.	0.2	5
33	One-tissue compartment model for myocardial perfusion quantification with N-13 ammonia PET provides matching results: A cross-comparison between Carimas, FlowQuant, and PMOD. Journal of Nuclear Cardiology, 2022, 29, 2543-2550.	1.4	5
34	Tandem myeloablative <sup>131</sup> I-rituximab radioimmunotherapy and high-dose chemotherapy in refractory/relapsed non-Hodgkin lymphoma patients. Immunotherapy, 2013, 5, 1283-1286.	1.0	3
35	Artificial nutrition in patients with cancer has no impact on tumour glucose metabolism: Results of the PETANC Study. Clinical Nutrition, 2019, 38, 2121-2126.	2.3	2
36	Antiviral (Hepatitis C Virus) Drug-Drug Interaction Leading to Dramatic Underestimation of Liver Function With <sup>99m</sup> Tc-Mebrofenin Hepatobiliary Scintigraphy. Clinical Nuclear Medicine, 2020, 45, 133-135.	0.7	2

#	ARTICLE	IF	CITATIONS
37	Implementation and validation of an in-house combined fluorescein/media-fill test to qualify radiopharmacy operators. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2021, 6, 2.	1.8	2
38	Prognostic value of metabolic signature on 18F-FDG uptake in breast cancer patients after radiotherapy. <i>Molecular Therapy - Oncolytics</i> , 2021, 23, 412-419.	2.0	2
39	Lumbosacral Plexus Neurolymphomatosis. <i>Clinical Nuclear Medicine</i> , 2022, 47, 352-353.	0.7	2
40	Myocardial perfusion quantification with Rb-82 PET: good interobserver agreement of Carimas software on global, regional, and segmental levels. <i>Annals of Nuclear Medicine</i> , 2022, 36, 507-514.	1.2	2
41	Imagerie de la néoangiogenèse en médecine nucléaire. <i>Medecine Nucleaire</i> , 2012, 36, 619-626.	0.2	1
42	Liver function: homogenous or not?. <i>Hpb</i> , 2016, 18, 871.	0.1	1
43	Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). , 2017, , .		1
44	Place de la TEP au 18FDG dans la localisation de primitifs néoplasiques. <i>Medecine Nucleaire</i> , 2009, 33, 508-511.	0.2	0
45	Value of 18FDG PET for prediction of therapeutic response in HER2+ breast cancer: Interim analysis. <i>Medecine Nucleaire</i> , 2020, 44, 181-188.	0.2	0
46	Unusual Focal Lung Uptake without CT Abnormality on a Bone Scan: What Might It Mean?. <i>Diagnostics</i> , 2022, 12, 934.	1.3	0
47	Whole body planar and 3D quantitative imaging after Lu-DOTATATE on CZT SPECT/CT device with MEHRS collimator. First report. <i>Hellenic Journal of Nuclear Medicine</i> , 2021, 24, 165-166.	0.2	0